X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MH002 is currently the most advanced rationally-designed consortium therapy, which is investigated for the treatment of mild-to-moderate Ulcerative Colitis.
Lead Product(s): MH002
Therapeutic Area: Gastroenterology Product Name: MH002
Highest Development Status: Phase II/ Phase IIIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
MRM Health, working in conjunction with International Flavors & Fragrances, is advancing the LBP candidate M008 for treating NAFLD/NASH. The proprietary MRM Health CORAL® technology platform and some IFF strains will be combined to develop novel therapeutics.
Lead Product(s): M008
Therapeutic Area: Endocrinology Product Name: M008
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: IFF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 12, 2022
Details:
MH002 is the first, rationally designed, consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical development in Pouchitis.
Lead Product(s): MH002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: MH002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Work demonstrated that 9-Strain Live Bacterial Consortium rationally selected gut commensal strains able to improve portal hypertension, insulin signaling and NAFLD activity score at histopathology, prevent fibrosis development in two different in vivo disease models of NASH.
Lead Product(s): 9-Strain Live Bacterial Consortia Therapeutic
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University Hospital of Vall d’Hebron
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
MH002 is the first rationally-designed consortium therapy consists of 6 well-characterized commensal strains that are optimized to form a synergistic microecosystem against mild-to-moderate ulcerative colitis.
Lead Product(s): MH002
Therapeutic Area: Gastroenterology Product Name: MH002
Highest Development Status: Phase I/ Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
In collaboration, proprietary MRM Health technology platform and some selected DuPont strains will be combined to develop novel therapeutics based on live bacterial strain combinations.
Lead Product(s): Gut microbiome based therapeutics
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: International Flavors and Fragrances
Deal Size: $15.1 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
